Sign In
Buy SENS
Senseonics Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | -$0.330 |
| EPS actual | -$0.430 |
| EPS Surprise | -30.30% |
| Revenue estimate | 14.219M |
| Revenue actual | 8.095M |
| Revenue Surprise | -43.07% |
| Release date | Aug 06, 2025 |
| EPS estimate | -$0.400 |
| EPS actual | -$0.400 |
| Revenue estimate | 6.022M |
| Revenue actual | 8.297M |
| Revenue Surprise | 37.78% |
| Release date | May 08, 2025 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0200 |
| Revenue estimate | 5.558M |
| Revenue actual | 6.257M |
| Revenue Surprise | 12.59% |
| Release date | Mar 03, 2025 |
| EPS estimate | -$0.0300 |
| EPS actual | -$0.0200 |
| EPS Surprise | 33.33% |
| Revenue estimate | 7.948M |
| Revenue actual | 8.297M |
| Revenue Surprise | 4.39% |
Last 4 Quarters for Senseonics
Below you can see how SENS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Mar 03, 2025 |
| Price on release | $17.40 |
| EPS estimate | -$0.0300 |
| EPS actual | -$0.0200 |
| EPS surprise | 33.33% |
| Date | Price |
|---|---|
| Feb 25, 2025 | $16.64 |
| Feb 26, 2025 | $17.58 |
| Feb 27, 2025 | $16.53 |
| Feb 28, 2025 | $17.00 |
| Mar 03, 2025 | $17.40 |
| Mar 04, 2025 | $14.04 |
| Mar 05, 2025 | $13.86 |
| Mar 06, 2025 | $12.28 |
| Mar 07, 2025 | $12.93 |
| 4 days before | 4.57% |
| 4 days after | -25.69% |
| On release day | -18.82% |
| Change in period | -22.30% |
| Release date | May 08, 2025 |
| Price on release | $14.74 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0200 |
| Date | Price |
|---|---|
| May 02, 2025 | $14.20 |
| May 05, 2025 | $13.41 |
| May 06, 2025 | $13.20 |
| May 07, 2025 | $13.80 |
| May 08, 2025 | $14.74 |
| May 09, 2025 | $12.50 |
| May 12, 2025 | $12.00 |
| May 13, 2025 | $11.91 |
| May 14, 2025 | $11.59 |
| 4 days before | 3.77% |
| 4 days after | -21.36% |
| On release day | -15.17% |
| Change in period | -18.39% |
| Release date | Aug 06, 2025 |
| Price on release | $9.73 |
| EPS estimate | -$0.400 |
| EPS actual | -$0.400 |
| Date | Price |
|---|---|
| Jul 31, 2025 | $9.70 |
| Aug 01, 2025 | $9.78 |
| Aug 04, 2025 | $10.16 |
| Aug 05, 2025 | $10.11 |
| Aug 06, 2025 | $9.73 |
| Aug 07, 2025 | $9.26 |
| Aug 08, 2025 | $9.91 |
| Aug 11, 2025 | $9.33 |
| Aug 12, 2025 | $9.47 |
| 4 days before | 0.330% |
| 4 days after | -2.71% |
| On release day | -4.87% |
| Change in period | -2.39% |
| Release date | Nov 05, 2025 |
| Price on release | $6.81 |
| EPS estimate | -$0.330 |
| EPS actual | -$0.430 |
| EPS surprise | -30.30% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $7.21 |
| Oct 31, 2025 | $7.05 |
| Nov 03, 2025 | $6.88 |
| Nov 04, 2025 | $6.69 |
| Nov 05, 2025 | $6.81 |
| Nov 06, 2025 | $6.22 |
| Nov 07, 2025 | $6.01 |
| Nov 10, 2025 | $6.35 |
| Nov 11, 2025 | $6.51 |
| 4 days before | -5.55% |
| 4 days after | -4.41% |
| On release day | -8.66% |
| Change in period | -9.71% |
Senseonics Earnings Call Transcript Summary of Q3 2025
Senseonics reported an exceptional Q3 2025 driven by strong adoption of Eversense 365. Key operational highlights: Q3 revenue grew 90% year-over-year to $8.1M (U.S. $6.4M), new patient shipments up ~160% YoY, new insertions +150% YoY, and the installed base +150% YoY. Direct-to-consumer (DTC) marketing materially scaled demand (digital leads +300% YoY; ~60% of new patients sourced from DTC in Q3). The company executed an MOU to reassume commercialization from Ascensia in the U.S. (targeted transition Jan 1, 2026) and is onboarding most Ascensia U.S. CGM employees; European transition and CE mark for Eversense 365 are expected in H1 2026 (CE mark still under final review). Eon Care (direct insertion service) is a growing distribution/enabler (~25% of U.S. insertions) and the company is pursuing pump integrations (notably Sequel’s twiist) for closed‑loop capability in 2026. Pipeline progress: IDE for Gemini on track Q4 2025 with U.S. approval planned late 2026; Freedom (transmitterless 365-day CGM) IDE expected H2 2026 and commercial target ~early 2028. Financials and guidance: Q3 gross profit $3.5M; net loss $19.5M ($0.43/share) vs. $24.0M prior year. Full-year 2025 revenue outlook ~ $35M; cash+restricted cash ~$111.3M (9/30/25); expected 2025 cash utilization ~ $60M. Margin outlook: gross profit margin now north of 40% YTD 2025, expected 35–40% full‑year 2025 (excluding certain accounting items), projected ~50% in 2026 from commercialization integration and ~70% at scale. Management plans to continue substantial DTC investment in 2026 and will provide initial 2026 guidance in early January.
